Rockville, MD – According to filings with the U.S. Securities and Exchange Commission, Ibex Biosciences is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Karlin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ibex Biosciences
Ibex Biosciences, LLC (Ibex) is a Delaware Limited Liability Company headquartered in Cumberland, Maryland. Unique to many early-stage biotechnology companies, Ibex engages in a diverse approach to research and development. Ibex strives to discover, validate, and produce potential solutions to a multitude of serious challenges facing human and ecological health by investing in exploratory projects and processes that may not have been validated within the public research community. Ibex is willing to take significant risk to fulfill its mission which is the relentless pursuit to effectively treat a vast number of unmet medical conditions plaguing humanity.

To learn more about Ibex Biosciences, visit http://www.ibex.bio/

Contact:
Michael Karlin, Chief Executive Officer
301-761-1500
https://www.linkedin.com/in/michaeljkarlin/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved